Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivity Disorder (ADHD) and Obesity

PHASE4TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Attention Deficit Hyperactivity DisorderGlucose IntoleranceObesity
Interventions
DRUG

Lis-dexamphetamine

Eligible subjects will be dispensed open label LDX (VyvanseTM). All subjects will start at 20 mg once a day dose and will be titrated up weekly by 10 mg increments up to a maximum dose of 70 mg. If a subject experiences intolerable side effects at a particular dose, a step down to the next tolerated level is allowed.

Trial Locations (1)

27705

Duke Child and Family Study Center, Durham

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Shire

INDUSTRY

lead

Duke University

OTHER